. 2006 Nov 10;63(5):575–582. doi: 10.1111/j.1365-2125.2006.02796.x

Table 2.

Changes from baseline in blood pressure (BP) and heart rate in extensive (EMs) and poor (PMs) metabolizers of CYP2D6 treated with nebivolol 5 mg (means; 95% CI)

	Week	EMs	PMs	P (EMs vs. PMs)
Trough effect
Systolic BP (mmHg)	2	−9.9 (−15.9, −3.8)^**	−11.6 (−18.9, −3.0)^*	0.736
	4	−11.7 (−15.5, −8.0)^***	−11.0 (−18.8, −3.2)^*	0.840
	8	−13.3 (−17.2, −9.4)^***	−10.7 (−17.6, −5.9)^**	0.520
	12	−10.8 (−14.1, −7.0)^***	−10.5 (−18.1, −6.8)^**	0.931
Diastolic BP (mmHg)	2	−9.6 (−12.2, −7.0)^***	−8.4 (−12.1, −4.8)^***	0.578
	4	−10.3 (−11.9, −8.7)^***	−9.1 (−11.1, −5.6)^***	0.333
	8	−11.8 (−13.6, −10.0)^***	−10.8 (−14.1, −7.6)^***	0.555
	12	−10.2 (−11.9, −8.5)^***	−9.3 (−6.3, −12.3)^***	0.542
Heart rate (beats min⁻¹)	2	−7.3 (−9.5, −5.1)^***	−2.1 (−6.6, 2.4)	0.019
	4	−8.9 (−12.9, −5.5)^***	−5.7 (−8.3, −3.2)^***	0.180
	8	−9.0 (−11.9, −6.2)^***	−5.8 (−9.3, −2.3)^**	0.149
	12	−9.2 (−12.0, −6.7)^***	−5.0 (−7.4, −2.3)^***	0.041
Peak effect
Systolic BP (mmHg)	4	−9.1 (−13.9, −4.3)^***	−8.4 (−12.8, −4.8)^***	0.848
	12	−7.8 (−12.9, −4.8)^***	−9.3 (−14.8, −5.9)^***	0.707
Diastolic BP (mmHg)	4	−6.2 (−9.1, −2.5)^**	−6.2 (−9.3, −3.2)^**	0.999
	12	−6.2 (−8.9, −3.5)^***	−8.0 (−11.0, −5.0)^***	0.374
Heart rate (beats min⁻¹)	4	−7.6 (−12.3, −2.9)^*	−2.4 (−6.7, 1.9)	0.121
	12	−5.1 (−8.1, −2.0)^**	−1.6 (−4.1, 1.7)	0.099

P < 0.05

^**

P < 0.01

^***

P < 0.0001 from baseline.